Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells

BACKGROUND: The combination of the reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib with gemcitabine obtained FDA approval for treating patients with pancreatic cancer. However, duration of response is often limited and there is currently no reliable predi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ioannou, N, Dalgleish, A G, Seddon, A M, Mackintosh, D, Guertler, U, Solca, F, Modjtahedi, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242519/
https://www.ncbi.nlm.nih.gov/pubmed/21970876
http://dx.doi.org/10.1038/bjc.2011.396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242519/
https://www.ncbi.nlm.nih.gov/pubmed/21970876
http://dx.doi.org/10.1038/bjc.2011.396

Ejemplares similares